Clinical trial
Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects…
NCT00460486 · Pfizer, Industry · Completed
Key facts
| NCT number | NCT00460486 |
|---|---|
| Title | Immunogenicity and Safety Study of FSME-IMMUN 0.5 mL in Adult Subjects Previously Vaccinated According to a Rapid Immunization Schedule |
| Official title | Open-Label Phase 3b Clinical Study to Evaluate the Immunogenicity and Safety of FSME-IMMUN 0.5 ml With the First and Second Vaccination Being Administered According to a Rapid Immunization Schedule in Healthy Adults Aged 16 Years or Older |
| Lead sponsor | Pfizer, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Encephalitis, Tick-Borne |
| Intervention type | Biological |
| Interventions | Formaldehyde inactivated, sucrose gradient purified TBE virus antigen, strain Neudörfl |
| Enrollment | 330 |
| Start date | Sep 1, 2006 |
| Primary completion | Nov 1, 2007 |
| First posted | Apr 16, 2007 |
| Last update posted | Apr 19, 2023 |
| Countries | Poland |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: